SG11201909115WA - Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof - Google Patents
Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereofInfo
- Publication number
- SG11201909115WA SG11201909115WA SG11201909115WA SG11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA
- Authority
- SG
- Singapore
- Prior art keywords
- street
- international
- compounds
- gsk3
- cambridge
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 102000001267 GSK3 Human genes 0.000 title abstract 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100176788 Dictyostelium discoideum gskA gene Proteins 0.000 title 1
- 101100149391 Drosophila melanogaster sgg gene Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 201000006347 Intellectual Disability Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762481981P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026339 WO2018187630A1 (en) | 2017-04-05 | 2018-04-05 | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909115WA true SG11201909115WA (en) | 2019-10-30 |
Family
ID=63712671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909115W SG11201909115WA (en) | 2017-04-05 | 2018-04-05 | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
Country Status (14)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2909204T1 (sl) | 2012-10-12 | 2019-06-28 | The Broad Institute, Inc. | Inhibitorji GSK3 in postopki njihove uporabe |
| CN110041349B (zh) * | 2019-05-15 | 2021-06-01 | 湖南科技大学 | 一种含螺二氢嘧啶衍生物及其制备方法和应用 |
| WO2023246820A1 (zh) * | 2022-06-20 | 2023-12-28 | 上海优替济生生物医药有限公司 | 体外诱导干细胞样记忆细胞的化合物及其应用 |
| TW202509014A (zh) | 2023-05-10 | 2025-03-01 | 美商纜圖藥品公司 | ＧＳＫ３α抑制劑及其使用方法 |
| WO2024259178A1 (en) | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Glycogen synthase kinase 3 inhibitors and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2722416A1 (de) | 1977-05-18 | 1978-11-30 | Thomae Gmbh Dr K | Neue thiazolo-pyridine |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| JPH05157164A (ja) | 1991-12-03 | 1993-06-22 | Aisin Aw Co Ltd | 車両用自動変速機のサーボ油圧制御装置 |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| CZ251995A3 (en) | 1993-04-08 | 1996-01-17 | Du Pont Merck Pharma | Disubstituted polycyclic compounds and their derivatives per se and for therapy as well as pharmaceutical compositions based thereon |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5750528A (en) | 1995-02-01 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| TW526202B (en) | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| US6977262B2 (en) | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| EP1355909A2 (en) | 2001-02-02 | 2003-10-29 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| DE10121217A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP1746097B1 (en) | 2005-07-20 | 2010-01-13 | Aventis Pharma S.A. | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US8778986B1 (en) | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
| US20090181986A1 (en) | 2007-07-05 | 2009-07-16 | Matthew Abelman | Substituted heterocyclic compounds |
| US9265764B2 (en) | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| SI2909204T1 (sl) * | 2012-10-12 | 2019-06-28 | The Broad Institute, Inc. | Inhibitorji GSK3 in postopki njihove uporabe |
| US20160375006A1 (en) | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| WO2015087996A1 (ja) | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | イミダゾピリジン誘導体 |
| KR101602559B1 (ko) | 2014-04-29 | 2016-03-10 | 경북대학교 산학협력단 | 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도 |
| ES2751602T3 (es) * | 2014-09-05 | 2020-04-01 | Merck Patent Gmbh | Compuestos diaza y triaza tricíclicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cáncer |
-
2018
- 2018-04-05 AU AU2018249558A patent/AU2018249558A1/en not_active Abandoned
- 2018-04-05 US US16/603,112 patent/US11203601B2/en active Active
- 2018-04-05 MX MX2019011987A patent/MX2019011987A/es unknown
- 2018-04-05 CN CN201880036981.1A patent/CN110958882B/zh active Active
- 2018-04-05 KR KR1020197032599A patent/KR20190136063A/ko not_active Withdrawn
- 2018-04-05 BR BR112019020810A patent/BR112019020810A2/pt not_active Application Discontinuation
- 2018-04-05 CA CA3058198A patent/CA3058198A1/en active Pending
- 2018-04-05 EA EA201992359A patent/EA201992359A1/ru unknown
- 2018-04-05 WO PCT/US2018/026339 patent/WO2018187630A1/en active Application Filing
- 2018-04-05 EP EP18781394.4A patent/EP3606528B1/en active Active
- 2018-04-05 SG SG11201909115W patent/SG11201909115WA/en unknown
- 2018-04-05 JP JP2019554982A patent/JP7157075B2/ja active Active
-
2019
- 2019-09-26 IL IL26970119A patent/IL269701A/en unknown
- 2019-10-31 CO CONC2019/0012324A patent/CO2019012324A2/es unknown
-
2021
- 2021-10-22 US US17/507,922 patent/US20220112216A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018249558A1 (en) | 2019-11-07 |
| EP3606528A1 (en) | 2020-02-12 |
| MX2019011987A (es) | 2020-07-14 |
| EP3606528A4 (en) | 2020-12-23 |
| JP7157075B2 (ja) | 2022-10-19 |
| EP3606528B1 (en) | 2023-10-18 |
| EA201992359A1 (ru) | 2020-03-12 |
| JP2020516616A (ja) | 2020-06-11 |
| WO2018187630A1 (en) | 2018-10-11 |
| CN110958882A (zh) | 2020-04-03 |
| IL269701A (en) | 2019-11-28 |
| BR112019020810A2 (pt) | 2020-04-28 |
| CO2019012324A2 (es) | 2020-05-15 |
| WO2018187630A8 (en) | 2019-01-03 |
| CA3058198A1 (en) | 2018-10-11 |
| US20200109154A1 (en) | 2020-04-09 |
| KR20190136063A (ko) | 2019-12-09 |
| US11203601B2 (en) | 2021-12-21 |
| US20220112216A1 (en) | 2022-04-14 |
| CN110958882B (zh) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909115WA (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane |